Cargando…
Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis
The aim of the present work is to extensively evaluate the pharmaceutical attributes of currently available riluzole presentations. The article describes the limitations and risks associated with the administration of crushed tablets, including the potential for inaccurate dosing and reduced rate of...
Autores principales: | Dyer, Ann Margaret, Smith, Alan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5191840/ https://www.ncbi.nlm.nih.gov/pubmed/28053507 http://dx.doi.org/10.2147/DDDT.S123776 |
Ejemplares similares
-
Administration of Riluzole Oral Suspension During the Different Stages of Amyotrophic Lateral Sclerosis
por: Povedano Panades, Mónica, et al.
Publicado: (2021) -
Riluzole and Edavarone: The Hope Against Amyotrophic Lateral Sclerosis
por: Rokade, Aditi V, et al.
Publicado: (2022) -
Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study
por: Introna, Alessandro, et al.
Publicado: (2018) -
Riluzole is associated with decreasing neuritic plaque severity in amyotrophic lateral sclerosis
por: Mazumder, Srestha, et al.
Publicado: (2022) -
Riluzole prescribing, uptake and treatment discontinuation in people with amyotrophic lateral sclerosis in Scotland
por: Jayaprakash, Kiran, et al.
Publicado: (2020)